American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan (Q83808238)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 2011

Language	Label	Description	Also known as
English	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan	scientific article published on 01 March 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan (English)

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Faramarz Ismail-Beigi

14

object named as

Faramarz Ismail-Beigi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Samuel Dagogo-Jack

7

object named as

Samuel Dagogo-Jack

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Harold E Lebovitz

18

object named as

Harold Lebovitz

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Paul S Jellinger

15

object named as

Paul S Jellinger

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Yehuda Handelsman

1

object named as

Yehuda Handelsman

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

George Grunberger

4

object named as

George Grunberger

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

13

object named as

Edward S Horton

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

12

object named as

Irl B Hirsch

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Lawrence Blonde

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Daniel Einhorn

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Om Ganda

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Lois Jovanovič

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Philip Levy

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

AACE Task Force for Developing Diabetes Comprehensive Care Plan

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Jeffrey I. Mechanick

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Zachary T. Bloomgarden

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

George A. Bray

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Jaime A. Davidson

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Alan J. Garber

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Edward S. Horton

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Kenneth L. Jones

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Harold Lebovitz

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Etie S. Moghissi

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Eric A. Orzeck

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Aaron I. Vinik

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

Kathleen L. Wyne

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21474420

29 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21474420

29 November 2024

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

March 2011

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21474420

29 November 2024

full work available at URL

https://api.elsevier.com/content/article/PII:S1530891X20432975?httpAccept=text/xml

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

https://api.elsevier.com/content/article/PII:S1530891X20432975?httpAccept=text/plain

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

http://aace.metapress.com/index/T7G5335740165V13.pdf

Portable Document Format

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Endocrine Practice

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

17 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

1-53

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

A1C Versus Glucose Testing: A Comparison

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.2337/DC10-1546

American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update

1

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists

2

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

3

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

4

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

5

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

6

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis

7

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

8

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis

9

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study

10

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

ISPAD clinical practice consensus guidelines 2009 compendium. Introduction

11

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes

12

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes

13

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006

14

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups

15

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum

16

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes

18

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

20

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

22

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

23

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

24

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

25

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

26

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Actos Now for the prevention of diabetes (ACT NOW) study

27

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

28

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study

29

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

30

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

31

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

32

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Meta-analysis: pharmacologic treatment of obesity

33

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

34

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-term mortality after gastric bypass surgery

35

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Predictors of long-term mortality after bariatric surgery performed in Veterans Affairs medical centers

36

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation

38

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The impact of weight reduction surgery on health-care costs in morbidly obese patients

39

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Are bariatric surgical outcomes worth their cost? A systematic review

40

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures

41

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

42

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients?

43

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function

44

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases.

45

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

46

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Swedish Obese Subjects (SOS) study--rationale and results

47

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus

49

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

50

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Critical assessment of the current guidelines for the management and treatment of morbidly obese patients

51

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

52

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

53

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

10-year follow-up of intensive glucose control in type 2 diabetes

54

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

55

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

56

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Normal fasting plasma glucose levels and type 2 diabetes in young men.

57

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Normal fasting plasma glucose levels and type 2 diabetes: the high-risk and population strategy for occupational health promotion (HIPOP-OHP) [corrected] study

58

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk

59

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucose control and vascular complications in veterans with type 2 diabetes

60

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of intensive glucose lowering in type 2 diabetes

61

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

62

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

63

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

66

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

68

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive versus conventional glucose control in critically ill patients

69

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Benefits and risks of tight glucose control in critically ill adults: a meta-analysis

70

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

71

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians

72

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive Insulin Therapy in Hospitalized Patients: A Systematic Review

73

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive insulin therapy in critically ill patients

74

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive insulin therapy in the medical ICU.

75

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glycemic variability: a strong independent predictor of mortality in critically ill patients

76

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucose variability and mortality in patients with sepsis.

77

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy

78

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

79

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease

80

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Patient characteristics associated with receipt of lifestyle behavior advice

81

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Food label use and awareness of nutritional information and recommendations among persons with chronic disease

82

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Position of the American Dietetic Association: vegetarian diets

83

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Grain foods and health: a primer for clinicians

85

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Benefits, barriers, self-efficacy and knowledge regarding healthy foods; perception of African Americans living in eastern North Carolina

86

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases

87

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Fiber facts: benefits and recommendations for individuals with type 2 diabetes

88

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Carbohydrate issues: type and amount

89

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Okinawan diet: health implications of a low-calorie, nutrient-dense, antioxidant-rich dietary pattern low in glycemic load

90

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The potential health benefits of legumes as a good source of dietary fibre

91

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Should glycemic index and glycemic load be considered in dietary recommendations?

92

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Impact of oil used by the frying industry on population fat intake

94

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis

95

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Meats, processed meats, obesity, weight gain and occurrence of diabetes among adults: findings from Adventist Health Studies.

96

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals

97

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence

98

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Trans fatty acids and cardiovascular health: translation of the evidence base

99

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary

101

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes.

102

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients

103

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Influence of Acute Exercise on Hyperglycemia in Insulin-Treated Type 2 Diabetes

104

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Exercise Training Improves Glycemic Control in Long-Standing Insulin-Treated Type 2 Diabetic Patients

105

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial

106

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis: response to Snowling and Hopkins

107

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES).

108

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

109

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucose Control, Self-Care Behaviors, and the Presence of the Chronic Care Model in Primary Care Clinics

110

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

111

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial

112

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

113

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

114

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin sulphonylurea: a meta-analysis

115

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

116

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

What role will 'gliptins' play in glycemic control?

117

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

118

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status

119

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c

120

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis

121

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Adiposity predicts cognitive decline in older persons with diabetes: a 2-year follow-up

122

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

123

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

124

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

126

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

127

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

128

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

129

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effects of pharmacologic agents for type 2 diabetes mellitus on body weight

130

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

131

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

132

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

133

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

134

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

135

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

136

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met TZD).

137

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

138

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

139

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met SU): a randomised controlled trial

140

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

141

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes

142

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

143

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

144

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

145

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

146

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

147

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

148

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

149

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

150

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis

151

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus

152

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

153

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

154

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Refining basal insulin therapy: what have we learned in the age of analogues?

155

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study

156

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin analogues

157

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis

158

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

159

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

160

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

161

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

162

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus

163

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

164

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis

166

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy

167

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous subcutaneous insulin infusion.

170

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes

172

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes,

173

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Statement by the American Association of Clinical Endocrinologists Consensus Panel on Insulin Pump Management

174

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin pump therapy: a meta-analysis

175

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis

176

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections

177

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion

178

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis

179

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective

180

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada

181

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

182

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Macrosomia in well controlled CSII treated Type I diabetic pregnancy.

183

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.

184

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes

185

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Activating mutations in the ABCC8 gene in neonatal diabetes mellitus

186

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood

187

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

188

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes

189

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Type 2 diabetes in children and adolescents. American Diabetes Association

190

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young

191

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree.

192

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes

193

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Screening for MODY mutations, GAD antibodies, and type 1 diabetes--associated HLA genotypes in women with gestational diabetes mellitus

195

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes

196

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus

197

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A longitudinal analysis of adherence and health status in childhood diabetes

198

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

199

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy

200

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships

201

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis

202

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Congenital Susceptibility to NIDDM: Role of Intrauterine Environment

203

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Standards of medical care in diabetes--2009.

204

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy

205

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience.

206

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog).

207

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.

208

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Use of insulin detemir during pregnancy

209

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Use of insulin detemir in pregnancy: a report on 10 Type 1 diabetic women

210

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Hyperglycemia and adverse pregnancy outcomes

211

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Standards of medical care in diabetes--2010.

212

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Low birth weight as a risk factor for gestational diabetes, diabetes, and impaired glucose tolerance during pregnancy

214

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Fetuses of obese mothers develop insulin resistance in utero

215

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Fetal and infant growth and impaired glucose tolerance at age 64.

216

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Multiple Hospitalizations for Patients With Diabetes

218

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Management of diabetes and hyperglycemia in hospitals

219

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Interference of home blood glucose measurements and poor outcomes: a solvable problem requiring broader exposure

220

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for statistical correlations

221

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects

222

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes

223

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

226

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diverse causes of hypoglycemia-associated autonomic failure in diabetes

227

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia

228

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes

229

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

ACE inhibitors and diabetic nephropathy

230

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

231

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Screening for kidney disease in adults with diabetes

232

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.

233

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?

234

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

235

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

236

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials

237

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.

238

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

239

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Preventing microalbuminuria in type 2 diabetes

240

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Aliskiren combined with losartan in type 2 diabetes and nephropathy

241

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

242

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis

243

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Specialist evaluation in chronic kidney disease: too little, too late

244

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant

245

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease

246

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-term complications of diabetes mellitus

247

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Epidemiology of diabetic retinopathy and macular oedema: a systematic review

248

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic retinopathy screening using digital non-mydriatic fundus photography and automated image analysis

249

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy

250

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis

251

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years

252

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group

253

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

254

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Treatment of diabetic retinopathy

255

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Photocoagulation for Diabetic Macular Edema

256

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Classification, Differential Diagnosis, and Staging of Diabetic Peripheral Neuropathy

257

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic neuropathies: a statement by the American Diabetes Association

258

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Neuropathic pain: redefinition and a grading system for clinical and research purposes

259

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation

260

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes

261

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort

262

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Vascular risk factors and diabetic neuropathy

263

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The natural history of acute painful neuropathy in diabetes mellitus

264

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Small fiber neuropathy is associated with the metabolic syndrome

265

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy

266

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Painful sensory polyneuropathy associated with impaired glucose tolerance

267

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prevalence of diabetic complications in relation to risk factors

269

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

270

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diagnosis and management of diabetic autonomic neuropathy

272

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Autoimmune mechanisms in peripheral neuropathies

273

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Balance training reduces falls risk in older individuals with type 2 diabetes

274

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial

275

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: a 6-month randomized, controlled trial.

276

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Problems with gait and posture in neuropathic patients with insulin-dependent diabetes mellitus

277

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Quantitative measurement of cutaneous perception in diabetic neuropathy

278

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the [...]

279

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments.

280

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fibre density in patients with normal nerve conduction studies

281

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Surrogate markers of small fiber damage in human diabetic neuropathy.

282

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The relationship among pain, sensory loss, and small nerve fibers in diabetes

283

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Lifestyle intervention for pre-diabetic neuropathy

284

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Role of experimental socks in the care of the high-risk diabetic foot. A multicenter patient evaluation study. American Group for the Study of Experimental Hosiery in the Diabetic Foot

285

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic somatic neuropathies

286

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials.

287

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Tools for assessing neuropathic pain

288

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy

289

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A systematic review of antidepressants in neuropathic pain

291

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.

292

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic cardiovascular autonomic neuropathy

293

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis

294

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

295

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The Approach to the Management of the Patient with Neuropathic Pain

296

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Neuropathy: the crystal ball for cardiovascular disease?

297

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic autonomic neuropathy

298

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group

299

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodia

301

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Why don't we teach and treat diabetic patients better?

302

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy

303

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy

304

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report

305

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie

306

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Thiazolidinediones-benefits on microvascular complications of type 2 diabetes

307

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Pioglitazone treatment improves nitrosative stress in type 2 diabetes

308

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes

309

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

310

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly

312

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Heart rate variability modifications following exercise training in type 2 diabetic patients with definite cardiac autonomic neuropathy

313

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of a group-based exercise program on balance in elderly

314

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy

315

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Is diabetes a coronary risk equivalent? Systematic review and meta-analysis

316

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

317

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects

318

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people

319

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The epidemiology of impaired glucose tolerance and hypertension.

320

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

321

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

322

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

323

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.

324

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart

325

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

326

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

327

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy

328

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.

329

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study

330

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004.

331

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study

332

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Hypertension in patients with diabetes. Strategies for drug therapy to reduce complications

333

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

335

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

336

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails

337

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

338

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prognostic value of ambulatory blood pressure : current evidence and clinical implications

339

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

340

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

341

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Diabetic dyslipidaemia: from basic research to clinical practice.

342

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

344

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

345

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

346

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

347

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

349

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Clinical practice. Hypertriglyceridemia

350

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).

352

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).

353

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study

354

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

355

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Refining lipoprotein assessment in diabetes: apolipoprotein B makes sense

356

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

357

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of combination lipid therapy in type 2 diabetes mellitus

358

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Major lipids, apolipoproteins, and risk of vascular disease

359

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

360

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

361

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Role of snoring and daytime sleepiness in occupational accidents

362

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Replication of restless legs syndrome loci in three European populations

363

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Obstructive sleep apnea and type 2 diabetes: interacting epidemics

364

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients

366

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea

367

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea.

368

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure

369

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea

370

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea

371

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

CPAP treatment of a population-based sample--what are the benefits and the treatment compliance?

372

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Depression and poor glycemic control: a meta-analytic review of the literature

373

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Increased mortality risk in women with depression and diabetes mellitus

374

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study

375

1 reference

10.4158/EP.17.S2.1

https://api.crossref.org/works/10.4158/EP.17.S2.1

29 November 2024

Identifiers

10.4158/EP.17.S2.1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21474420 AND SRC:MED&resulttype=core&format=json

27 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83808238&oldid=2281199616"